The runner with chronic tendinopathy — what conventional care often misses
9 min read · Uplevel editorial
The Achilles has been a problem for eighteen months. Not acutely painful — you learned early on that "playing through" sharp Achilles pain leads somewhere you don't want to go — but a persistent morning stiffness that takes half a mile to work out, a low-grade ache that settles in after longer runs, a sensitivity to load that forces you to cap your mileage below what your fitness could otherwise support. You've done the rest. You've done the eccentric heel drops — three sets of fifteen on each leg, twice a day, for three months — the way every protocol told you to. You've had the cortisone injection that helped for six weeks and then reverted. You've tried the massage and the stretching and the new shoes and the gait analysis, and the Achilles is still there, still the ceiling on your training, still the thing that's been quietly running your schedule for a year and a half.
What your Achilles has is not tendinitis. It probably hasn't been tendinitis for a long time, if it ever was. And that misclassification — one that your running coach, your physical therapist, and possibly your orthopedist may have been perpetuating — is part of why the treatments designed for inflammation haven't fixed it.
Tendons are designed for one thing: efficient force transmission between muscle and bone. They do this through densely organized parallel collagen fibers — primarily Type I collagen — that run along the axis of load. The collagen turnover in healthy tendon is slow by biological standards: tendon tissue has a half-life measured in years, not weeks, and vascularization is minimal compared to muscle. Tendon heals slowly because it's designed to be metabolically quiet. It doesn't need constant rebuilding because, in a healthy state, it rarely breaks down.
Tendinopathy — the term that has largely replaced tendinitis in the sports medicine and orthopedic literature over the past twenty years — is not an inflammatory condition in the primary sense. It's a degenerative and failed healing response. Under chronic overload — running mileage that exceeds the tendon's adaptation capacity, or mileage increased too quickly for the slow collagen remodeling cycle to keep pace — the organized parallel collagen architecture begins to break down. The collagen fibers become disorganized and fragmented, ground substance increases between fibers, fibroblasts in the affected region show dysfunction, and the tendon tries to respond by growing new blood vessels into tissue that was previously avascular. This neovascularization — the growth of new blood vessels — brings sensory nerve fibers with it, which is likely why chronic tendinopathy produces pain in response to load long after any acute inflammatory phase has resolved. The pain is not signaling active inflammation. It's signaling dysfunctional tissue with nerves that shouldn't be there.
This is the central insight that reframes the treatment question. Anti-inflammatory approaches — NSAIDs, corticosteroid injections — target a process that is not the primary problem in established tendinopathy. Corticosteroid injection may reduce pain in the short term, largely by suppressing the local pain response and reducing what modest inflammation is present, but it does nothing to address the disorganized collagen and may in fact impair tenocyte function and slow the structural recovery that the tendon needs. The short-term relief followed by return to baseline — or worse — that many runners experience after corticosteroid injection is consistent with this mechanism. You reduced the symptom. You didn't change the tissue.
The load-based rehabilitation that has emerged as the evidence-based standard — specifically progressive tendon loading starting with isometric exercises, moving through isotonic, and eventually toward sport-specific load — works because it is the correct stimulus for the correct problem. Mechanical load, applied progressively and at appropriate intensity, signals tenocytes to produce collagen, promotes remodeling of disorganized collagen toward aligned structure, and over time can restore tendon architecture toward health. The eccentric heel drop protocol is one expression of this principle. The reason it works when it works — and why it doesn't work for everyone — is that tendon remodeling is slow, the load must be calibrated correctly to stimulate adaptation without exceeding capacity, and biomechanical factors that are overloading the tendon need to be identified and addressed or the cycle continues. Running mechanics, calf strength and flexibility, foot strike pattern, training surface, and weekly load accumulation all feed into the equation.
What biomechanical factors are perpetuating the load? This is the question that is most often inadequately answered in conventional tendinopathy care. A physical therapist who is treating your Achilles without a thorough assessment of your running gait, your hip and ankle strength, and your training load history is working with incomplete information. The Achilles is the target of the problem, not necessarily the source of it. Proximal weakness — particularly in the glutes and hip stabilizers — shifts load distally. Calf stiffness changes the mechanics of the Achilles loading cycle. Training load spikes create tendon stress that exceeds the remodeling rate. Any of these can perpetuate the tendinopathy regardless of what is done locally at the tendon.
The peptide research enters this picture at the level of tissue biology — specifically at the question of whether anything can support the structural repair capacity of a tissue that heals slowly and in which conventional rehabilitation has been slow to produce results. BPC-157 has generated the most research attention in this context. In rodent tendon injury models, BPC-157 has consistently shown accelerated healing, improved collagen organization, and increased tendon strength in treated animals compared to controls. The proposed mechanisms include support for fibroblast and tenocyte activity through growth factor pathways, promotion of angiogenesis in tissue that lacks adequate blood supply to drive healing, and modulation of nitric oxide signaling, which plays a regulatory role in tendon mechanotransduction. The animal data is consistent across multiple research groups and injury models. The human evidence is limited — clinical trials in tendinopathy specifically are sparse, most clinical use is off-label and supervised by providers in sports medicine and integrative orthopedic contexts, and effect size in humans has not been characterized in controlled research. The compound is not FDA-approved and is used as a compounded preparation when prescribed.
TB-500 — synthetic Thymosin Beta-4 — is researched alongside BPC-157 in tissue healing contexts. Its primary mechanism involves actin polymerization and cell migration: it promotes the movement of repair cells toward damaged tissue and supports angiogenesis through a different pathway than BPC-157. In some clinical settings, BPC-157 and TB-500 are used together under the hypothesis that their mechanisms are complementary — one targeting the growth factor and receptor pathway, one targeting cell motility and vascular supply. The evidence base for this combination is preclinical; the human rationale is mechanistic inference rather than clinical trial data.
GHK-Cu — the copper peptide tripeptide — is peripherally relevant through its role in collagen synthesis and matrix metalloproteinase regulation. MMPs are the enzymes that degrade and remodel collagen matrix; their activity needs to be appropriately regulated during tendon healing to avoid excessive degradation. GHK-Cu's effects on MMP regulation and collagen production have been studied primarily in wound healing and skin contexts; translation to tendon biology is speculative but mechanistically plausible.
GH axis support — Sermorelin, Ipamorelin — connects to tendon recovery through the general role of GH and IGF-1 in collagen synthesis and tissue repair. GH-deficient individuals have documented impairments in connective tissue maintenance, and GH replacement in deficient patients improves collagen turnover markers. Whether GH axis support in a non-deficient athlete with tendinopathy produces meaningful tendon structural benefit is not established in clinical research, but the mechanism is coherent.
The injection route question is worth addressing directly because it comes up in clinical discussions around BPC-157 and tendinopathy. Systemic subcutaneous injection — the most common route in clinical use — delivers the compound into the general circulation, from which it would need to reach tendon tissue. Some providers explore locally directed injection — closer to the affected tendon — under the hypothesis that higher local concentration may improve efficacy. The safety and efficacy data on intratendinous injection of BPC-157 specifically does not exist in clinical literature; most sports medicine providers who use it prefer the systemic or peritendinous route rather than injecting directly into the tendon substance, which carries its own mechanical risk.
The honest framing on peptides and tendinopathy is this: the rodent data is encouraging enough that serious researchers are paying attention, and clinicians in sports medicine and integrative orthopedics are applying these compounds in supervised, off-label contexts with some reported clinical success. The human evidence is limited and largely anecdotal. If you've been working through a tendinopathy rehabilitation program correctly — progressive loading, appropriate biomechanical corrections, adequate training load management — and you've hit a wall where the structural recovery isn't progressing, the peptide conversation is a reasonable one to have. It is not a replacement for the rehabilitation work. It is a potential biological support for tissue that heals slowly and may need more than load alone to reorganize.
The most useful clinical conversation is with a sports medicine specialist who understands tendinopathy biology specifically — not just injury management generically — and who is familiar with the current state of peptide research in tissue healing. That overlap is not universal in sports medicine, but it exists, particularly in practices that work with masters athletes, competitive runners, and people with chronic musculoskeletal issues that haven't resolved through conventional care. If your tendinopathy has been managed primarily as inflammation for months or years, and the treatment has produced temporary relief but not structural resolution, the conversation about what is actually happening in the tissue — and what biology might support its repair — is one worth having with someone who can address both questions at once.
Frequently asked